New pill ZT006 aims to shed pounds in obesity trial
Disease control
Ongoing
This study tests a new tablet, ZT006, for weight loss in 184 overweight or obese adults. Participants take either ZT006 or a placebo daily for 28 weeks, with the dose slowly increased to help tolerance. The main goal is to see how much weight people lose. This is a Phase 2 trial,…
Phase: PHASE2 • Sponsor: Beijing QL Biopharmaceutical Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 11:31 UTC